{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:54:35Z","timestamp":1793361275602,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019832","name":"Galapagos","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Galapagos and Gilead Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In the TORTUGA trial, patients with AS received filgotinib 200\u2009mg (n\u2009=\u200958) or placebo (n\u2009=\u200958) once daily for 12\u2009weeks. In this post hoc analysis, spine MRIs were evaluated using the Canada\u2013Denmark (CANDEN) MRI scoring system to assess changes from baseline to week 12 in total spine and subscores for inflammation, fat, erosion and new bone formation (NBF) at various anatomical locations. Correlations were assessed between CANDEN inflammation and clinical outcomes and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI scores and between baseline CANDEN NBF and baseline BASFI and BASMI scores.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>MRIs from 47 filgotinib- and 41 placebo-treated patients were evaluated. There were significantly larger reductions with filgotinib vs placebo in total spine inflammation score and most inflammation subscores, including posterolateral elements (costovertebral joints, transverse\/spinous processes, soft tissues), facet joints and vertebral bodies. No significant differences were observed for corner or non-corner vertebral body inflammation subscores, spine fat lesion, bone erosion or NBF scores. In the filgotinib group, the change from baseline in the total inflammation score correlated positively with the SPARCC spine score. Baseline NBF scores correlated with baseline BASMI but not BASFI scores.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Compared with placebo, filgotinib treatment was associated with significant reductions in MRI measures of spinal inflammation, including in vertebral bodies, facet joints and posterolateral elements.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov (https:\/\/clinicaltrials.gov), NCT03117270.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab758","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:08:43Z","timestamp":1634083723000},"page":"2388-2397","source":"Crossref","is-referenced-by-count":24,"title":["Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-1755","authenticated-orcid":false,"given":"Walter P","family":"Maksymowych","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alberta , Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[{"name":"Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Center of Head and Orthopedics, Rigshospitalet , Glostrup"},{"name":"Department of Clinical Medicine, University of Copenhagen , Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert","family":"Landew\u00e9","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center , Amsterdam"},{"name":"Department of Rheumatology, Zuyderland Medical Center , Heerlen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Barchuk","sequence":"additional","affiliation":[{"name":"Clinical Research, Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Research, Gilead Sciences, Inc. , Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leen","family":"Gilles","sequence":"additional","affiliation":[{"name":"Biometrics, Galapagos NV , Mechelen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Hendrikx","sequence":"additional","affiliation":[{"name":"Medical Affairs"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8699-4549","authenticated-orcid":false,"given":"Robin","family":"Besuyen","sequence":"additional","affiliation":[{"name":"Clinical Development, Galapagos BV , Leiden, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[{"name":"Rheumazentrum Ruhrgebiet Herne, Ruhr-University , Bochum, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"2022060107573114600_keab758-B1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2040622317743486","article-title":"New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice","volume":"9","author":"Dubash","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"2022060107573114600_keab758-B2","first-page":"889","article-title":"One year in review 2018: axial spondyloarthritis","volume":"37","author":"Carli","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2022060107573114600_keab758-B3","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"2022060107573114600_keab758-B4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022060107573114600_keab758-B5","first-page":"712","article-title":"Imaging in axial spondyloarthritis","volume":"19","author":"Baraliakos","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"2022060107573114600_keab758-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3899\/jrheum.141402","article-title":"Magnetic resonance imaging\u2014key to understanding and monitoring disease progression in spondyloarthritis?","volume":"42","author":"\u00d8stergaard","year":"2015","journal-title":"J Rheumatol"},{"key":"2022060107573114600_keab758-B7","doi-asserted-by":"crossref","first-page":"R104","DOI":"10.1186\/ar2496","article-title":"The relationship between inflammation and new bone formation in patients with ankylosing spondylitis","volume":"10","author":"Baraliakos","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2022060107573114600_keab758-B8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/annrheumdis-2011-200208","article-title":"MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis","volume":"71","author":"van der Heijde","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022060107573114600_keab758-B9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.24132","article-title":"Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation","volume":"60","author":"Maksymowych","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022060107573114600_keab758-B10","doi-asserted-by":"crossref","first-page":"e0135206","DOI":"10.1371\/journal.pone.0135206","article-title":"Fat metaplasia on sacroiliac joint magnetic resonance imaging at baseline is associated with spinal radiographic progression in patients with axial spondyloarthritis","volume":"10","author":"Kang","year":"2015","journal-title":"PLoS One"},{"key":"2022060107573114600_keab758-B11","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/art.30393","article-title":"Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis","volume":"63","author":"Chiowchanwisawakit","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2022060107573114600_keab758-B12","doi-asserted-by":"crossref","first-page":"e000399","DOI":"10.1136\/rmdopen-2016-000399","article-title":"Fat metaplasia on MRI of the sacroiliac joints increases the propensity for disease progression in the spine of patients with spondyloarthritis","volume":"3","author":"Maksymowych","year":"2017","journal-title":"RMD Open"},{"key":"2022060107573114600_keab758-B13","first-page":"3","article-title":"Active inflammatory lesions detected by magnetic resonance imaging in the spine of patients with spondyloarthritis \u2013 definitions, assessment system, and reference image set","volume":"84","author":"Lambert","year":"2009","journal-title":"J Rheumatol"},{"key":"2022060107573114600_keab758-B14","first-page":"18","article-title":"Structural lesions detected by magnetic resonance imaging in the spine of patients with spondyloarthritis \u2013 definitions, assessment system, and reference image set","volume":"84","author":"\u00d8stergaard","year":"2009","journal-title":"J Rheumatol"},{"key":"2022060107573114600_keab758-B15","doi-asserted-by":"crossref","first-page":"e000624","DOI":"10.1136\/rmdopen-2017-000624","article-title":"Inflammatory and structural changes in vertebral bodies and posterior elements of the spine in axial spondyloarthritis: construct validity, responsiveness and discriminatory ability of the anatomy-based CANDEN scoring system in a randomised placebo-controlled trial","volume":"4","author":"Krabbe","year":"2018","journal-title":"RMD Open"},{"key":"2022060107573114600_keab758-B16","doi-asserted-by":"crossref","first-page":"e001057","DOI":"10.1136\/rmdopen-2019-001057","article-title":"Canada-Denmark MRI scoring system of the spine in patients with axial spondyloarthritis: updated definitions, scoring rules and inter-reader reliability in a multiple reader setting","volume":"5","author":"Krabbe","year":"2019","journal-title":"RMD Open"},{"key":"2022060107573114600_keab758-B17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022060107573114600_keab758-B18"},{"key":"2022060107573114600_keab758-B19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"2022060107573114600_keab758-B20","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"2022060107573114600_keab758-B21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/art.21337","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022060107573114600_keab758-B22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.21445","article-title":"Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis","volume":"53","author":"Maksymowych","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2022060107573114600_keab758-B23","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.10883","article-title":"Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2022060107573114600_keab758-B24","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/art.21563","article-title":"Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial","volume":"54","author":"Haibel","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022060107573114600_keab758-B25","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/annrheumdis-2018-214983","article-title":"What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis","volume":"78","author":"Baraliakos","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2022060107573114600_keab758-B26","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","article-title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","volume":"56","author":"van der Heijde","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2022060107573114600_keab758-B27","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022060107573114600_keab758-B28","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1186\/ar4464","article-title":"Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers","volume":"16","author":"Wei\u00df","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2022060107573114600_keab758-B29","doi-asserted-by":"crossref","first-page":"iv43","DOI":"10.1093\/rheumatology\/kex419","article-title":"Osteoarthritis: the genesis of pain","volume":"57","author":"Fu","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2022060107573114600_keab758-B30","article-title":"Chronic pain and assessment of pain sensitivity in patients with axial spondyloarthritis: results from the SPARTAKUS cohort","author":"Mogard","year":"2020","journal-title":"J Rheumatol"},{"key":"2022060107573114600_keab758-B31","first-page":"467","article-title":"Spinal mobility in the cervical and lumbar spine correlates with magnetic resonance imaging findings for inflammatory and structural changes in patients with active ankylosing spondylitis","volume":"38","author":"Baraliakos","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2022060107573114600_keab758-B32","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/ard.2009.124206","article-title":"Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis","volume":"69","author":"Machado","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2022060107573114600_keab758-B33","doi-asserted-by":"crossref","first-page":"e001356","DOI":"10.1136\/rmdopen-2020-001356","article-title":"Determining factors related to impaired spinal and hip mobility in patients with axial spondyloarthritis: longitudinal results from the DESIR cohort","volume":"6","author":"Carvalho","year":"2020","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab758\/41048848\/keab758.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2388\/43891918\/keab758.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/6\/2388\/43891918\/keab758.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T08:01:10Z","timestamp":1654070470000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/6\/2388\/6396882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,14]]},"published-print":{"date-parts":[[2022,5,30]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab758","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,10,14]]}}}